Last reviewed · How we verify
NCT03535766: TRACE
An Analysis of Treatment Timelines for Lung Cancer Patients Across System Evolutions
trial in Lung Cancer in 2,100 participants. Completed in 9 January 2023.
1 July 2021
Quick facts
| Lead sponsor | St Elizabeth Healthcare |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,100 |
| Start date | 1 March 2018 |
| Primary completion | 1 July 2021 |
| Estimated completion | 9 January 2023 |
| Sites | 1 location across United States |
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
St Elizabeth Healthcare
Who can join
18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single center, minimal risk, physician initiated retrospective chart review. An analysis of treatment timelines for patients diagnosed with lung cancer within the St. Elizabeth system from January 2013 until study completion. The study investigator and designee(s) will review patient electronic medical records, extracting data related to the symptom presentation, diagnosis, and treatment of new diagnoses of lung cancer. Collected data will focus on dates of encounters, diagnostic imaging/procedures, and treatments, with data analysis evaluating time between care encounters and potential delays in care. The data will be further stratified based on system-wide changes implemented to improve efficiency, patient outcomes, and patient experience.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review.
Hall H, Tocock A, Burdett S, Fisher D, et al · · 2022 · cited 37× · PMID 34404753 · DOI 10.1136/thoraxjnl-2021-216865
Verify or expand the search:
- PubMed search for NCT03535766
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other St Elizabeth Healthcare trials
Trials by the same sponsor.
- NCT03560791 — A Review of Low-Dose CT Lung Cancer Screenings in a Community-Based Healthcare System With High Incidence · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03535766 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by St Elizabeth Healthcare
- Last refreshed: 12 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03535766.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing